博苏替尼 (bosutinib) 在伦巴第 (Lombardy) 治疗慢性髓性白血病
Alessandra Iurlo1, Cristina Bucelli1, Tamara Intermesoli2
1Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Acta haematologica
|September 18, 2024
概括
博苏替尼 (BOS) 是慢性髓性白血病 (CML) 患者的有效治疗方法,这些患者不能耐受或对其他类铁激酶抑制剂 (TKI) 具有抗性. 现实数据显示,BOS可以达到高分子响应率,即使是在后期的治疗线.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 高达30%的慢性髓性白血病 (CML) 患者需要改变治疗,原因是不耐受或对一线氨酸激酶抑制剂 (TKI) 的耐药性.
- 博苏替尼 (BOS) 提供了有利的安全性和疗效,由于伴随性疾病,没有绝对的禁忌.
研究的目的:
- 评估用博苏替尼 (BOS) 治疗的CML患者的现实结果.
- 评估BOS疗效和安全性,先前接受其他TKI治疗的患者.
主要方法:
- 在伦巴第血液学网络 (REL) 的18个血液学中心接受BOS的132名CML患者的回顾性分析.
- 在治疗线上收集的数据,转换到BOS (不耐受性与耐药性) 的原因以及患者的结局.
主要成果:
- 大多数患者 (62.9%) 在第二线接受了BOS,主要是由于不耐受 (63.6%) 以往的TKIs.
- 超过80%的患者至少获得了主要分子响应 (MMR).
- 七名患者能够尝试无治疗缓解 (TFR).
结论:
- 博苏替尼 (Bosutinib,简称BOS) 是对以前的TKI不耐受的CML患者的首选选择.
- 在现实世界的临床实践中,BOS证明了安全性和有效性,作为一种超越第一线的治疗选择.
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
139
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
139
Bone Marrow Sampling and Transplants
313
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
313
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98


